Business Wire

MILREM-ROBOTICS

14.9.2021 09:02:12 CEST | Business Wire | Press release

Share
Milrem Robotics to Develop the Nordic Robotic Wingman With Kongsberg Defence & Aerospace

The leading European robotics and autonomous systems developer Milrem Robotics is to develop a new Robotic Combat Vehicle (RCV) named Nordic Robotic Wingman in cooperation with the leading technology and defence supplier, Kongsberg Defence & Aerospace (KONGSBERG).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005044/en/

The Nordic Robotic Wingman will be based on Milrem Robotics’ state of the art Type-X RCV and KONGSBERG’s latest and best PROTECTOR Remote Turrets (RT) that will be chosen specifically to meet the particular needs of various end-users.

The first Nordic Robotic Wingman concept will be exhibited at DSEI 2021 in London.

“Milrem Robotics and KONGSBERG have agreed to jointly continue the development of the Type-X RCV by integrating KONGSBERG’s systems to address the requirements of many countries interested in this type of technology, especially the Nordics and Western Europe, but also the US,” said Sverker Svärdby, Managing Director of Milrem Robotics’ Sweden. “Combining our knowledge of robotic combat vehicles and KONGSBERG’s wide range of systems and extensive expertise in defence systems development, we are capable of providing world-class systems based on customer needs,” Svärdby added.

The Type-X provides equal or overmatching firepower and tactical usage to a unit equipped with Infantry Fighting vehicles and gives mechanized units the means to breach enemy defensive positions with minimal risk to own troops. It can be fitted with a cannon up to 50 mm, anti-tank missiles and a tethered drone for continuous situational awareness.

“KONGSBERG has a family of unmanned PROTECTOR Remote Weapon Systems, ranging from the smallest RS2 Remote Weapon Station to the true Infantry Fighting Vehicle turret RT60 with Anti-Tank Guided Missile capability. The systems have a common software baseline, are easy to integrate and provide proven capabilities for the warfighter. KONGSBERG’s solution provides the operator with situational awareness and a safe and secure network-based fire control that is fielded with the Norwegian Army and in delivery to the US Army’s Robotic Combat Vehicle program,” said Arne Gjennestad, Vice President of Marketing & Sales, KONGSBERG.

Milrem Robotics’ Type-X is equipped with intelligent functions such as follow-me, waypoint navigation and obstacle detection with Artificial Intelligence being part of the algorithms. With the Type-X Milrem Robotics also introduces a feature called Indirect Drive that allows remote controlled operations on higher speeds.

Milrem Robotics is the European leading robotics and autonomous systems developer and systems integrator with offices in Estonia, Sweden, Finland and shortly in the Netherlands.

The company leads the iMUGS Consortium that was awarded 30,6 MEUR from the European Commission’s European Defence Industrial Development Programme (EDIDP) to develop a European standardized unmanned ground system (UGS).

Kongsberg Defence & Aerospace is a leading supplier of defence products and systems for command and control, surveillance, space, tactical communications, remote weapon stations and missiles, as well as advanced composites, engineering products and repair and overhaul services for aircraft and helicopters.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye